Novo Nordisk Enters Its First Strategic RNAi Pact
Alliance With Dicerna To Explore More Than 30 targets
Novo Nordisk’s head of global drug discovery tells Scrip he hopes the strategic collaboration with Dicerna Pharmaceuticals will generate clinical candidates within three years.
You may also be interested in...
Novo Nordisk is paying $725m to acquire the VC-backed US biotech, Corvidia Therapeutics and its promising Phase II candidate, ziltivekimab, for chronic kidney disease, but further payments could total more than $2bn.
Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.
Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.